GlassScriptPhysician profile
Edward Flores
NPI 1912922386
$5,059.15
in general payments reported to CMS, 2019-2025
35 companies · $927 in 2025
The $927 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $250 · 2020: $114 · 2021: $846 · 2022: $666 · 2023: $854 · 2024: $1,401 · 2025: $927.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,124 · Education: $57.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,124.03 |
| Education | $57.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,507.09 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,237.28 | 2021-2025 | Fasenra, Airsupra, Tezspire |
| Insmed, INC. | $210.73 | 2021-2024 | Arikayce |
| Philips North America LLC | $210.02 | 2019-2024 | (Ak6) Vest Therapy, (8874) Incourage |
| Regeneron Healthcare Solutions, INC. | $162.53 | 2022-2024 | Libtayo, Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.92 | 2019-2024 | Ofev |
| Mallinckrodt Hospital Products INC. | $124.19 | 2022 | |
| Genzyme Corporation | $114.37 | 2022-2025 | |
| United Therapeutics Corporation | $110.48 | 2021-2024 | Orenitram, Remodulin, Tyvaso |
| Janssen Pharmaceuticals, INC | $109.58 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $108.20 | 2025 | |
| Pfizer INC. | $103.87 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $85.22 | 2022-2024 | |
| Grifols USA, LLC | $85.18 | 2022-2024 | Prolastin-C Liquid |
| Sunovion Pharmaceuticals INC. | $71.34 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $61.73 | 2022-2025 | Glassia |
| Leo Pharma INC. | $56.87 | 2024-2025 | Adbry |
| Baxter Healthcare | $55.94 | 2023-2025 | Hillrom - Vest System Model 105 Home Care |
| Harmony Biosciences LLC | $51.77 | 2024-2025 | |
| Amgen INC. | $50.37 | 2021-2025 | Tezspire |
| Verona Pharma, INC. | $43.87 | 2025 | Ohtuvayre |
| Inspire Medical Systems, INC. | $42.26 | 2025 | Inspire |
| Genentech USA, INC. | $41.84 | 2019 | |
| Merck Sharp & Dohme LLC | $39.98 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $39.82 | 2024 | Purified Cortrophin Gel |
| Lilly USA, LLC | $31.48 | 2024-2025 | Mounjaro, Zepbound |
| Actelion Pharmaceuticals US, INC. | $30.40 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.30 | 2019 | |
| Vifor Pharma, INC. | $22.38 | 2024 | Zemaira |
| Seqirus USA INC | $18.26 | 2025 | Flucelvax, Fluad |
| Advanced Respiratory, INC | $17.30 | 2019 | |
| Electromed, INC. | $16.93 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $16.29 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $13.18 | 2024 | Rexulti |
| Inogen, INC. | $8.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Flores listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.